[Comparative clinical and epidemiological evaluation of beta-lactam antibiotics in the treatment of intraabdominal infections].
We performed a retrospective, comparative study to evaluate efficacy, safety and economic outcomes of empiric cefoperazone/sulbactam monotherapy compared with the meropenem, imipenem/cilastatine and combination of cefepime plus metroindazol in patients with intra-abdominal infection. A total of 468 patients diagnosed with intra-abdominal abscess, peritonitis, pancreatitis were included in the study (the severity of infection according to scale APACHE II was less than 15). Patients were randomized to be treated with either 500 mg meropemen i.v. every 8 hours or 500 mg imipenem/cilastatine i.v. every 8 hours or 2 g cefepime i.v. every 12 hours plus 500 mg metronidazol twice daily or cefoperazone/sulbactam 2 g daily administered every 12 hours. Overall positive clinical responses (cure or improvement) were achieved at the end of treatment for 87.5 patients in meropenem group, 86.6% in the imipenem/cilastatin group, 85.3% in the cefepime group and 86.8% in cefoperazone/sulbactam group. Total cost of the treatment per 100 patients with intra-abdominal infections for cefoperazone/sulbactam was 1957031 roubles, for combinations of cefepime with metronidazol--2497815 roubles. For carbapenem group cost achieved for meropenem--3085291 rub., for imipenem/cilastatin--2653388 roubles. Rate "cost-effectiveness" in total: 784.47$ for cefepime, and 834.39$ for imipenem/cilastatine, 970.21$ for meropenem and 615.4$ for cefoperazone/sulbactam. The most expensive treatment was considered to be with meropenem and imipenem/cilastatine, main share is determined by initial cost of preparations. Less expensive was treatment by cefoperazone/sulbactam with cefepime and by metronidazol.
Beketov
A S
AS
National Research Centre of Antibiotics, Moscow.
Sidorenko
S V
SV
Pisarev
V V
VV
Komarov
R M
RM
D000005:Abdomen; D000900:Anti-Bacterial Agents / Q000191:economics* / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy / Q000191:economics* / Q000209:etiology; D000077723:Cefepime; D002438:Cefoperazone / Q000191:economics / Q000627:therapeutic use; D002511:Cephalosporins / Q000191:economics / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003365:Costs and Cost Analysis; D004338:Drug Combinations; D006801:Humans; D015378:Imipenem / Q000191:economics / Q000627:therapeutic use; D000077731:Meropenem; D018803:Models, Economic; D013407:Sulbactam / Q000191:economics / Q000627:therapeutic use; D013845:Thienamycins / Q000191:economics / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D004338:Drug Combinations; D013845:Thienamycins; D015378:Imipenem; D002438:Cefoperazone; D000077723:Cefepime; C057923:sulperazone; D000077731:Meropenem; D013407:Sulbactam